September 21st, 2026Children With Chronic Conditions Face Higher Pneumococcal Disease CostsData show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.Read more
September 15th, 2026Genomic Surveillance Key in Combating Pneumococcal MeningitisA persistence of pneumococcal meningitis among adults transformed the disease into a public health concern pharmacists fight on a population-wide scale.Read more
September 15th, 2026Childhood Pneumonia Hospitalizations Fell Sharply After PCV13 IntroductionAn analysis found all-cause pneumonia Black, lower-income, and medically at-risk children still face substantially higher rates of hospitalization.Read more
September 21st, 2026Pharmacy Workforce Suicide Awareness Day Aiming for Federal RecognitionObserved by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.Read more
September 21st, 2026Atogepant Meets End Points in Menstrual Migraine TrialAtogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.Read more
September 21st, 2026How the Main Street Pharmacy Access Act Advances Pharmacist Provider StatusChad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.Read more
September 20th, 2026Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except SpeechResearchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.Read more
September 19th, 2026Oveporexton Met Primary, Key Secondary End Points in Phase 3 StudiesResults show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.Read more